Amicus Therapeutics Completes Merger with BioMarin, Becomes Wholly-Owned Subsidiary

summarizeSummary

Amicus Therapeutics, Inc. has completed its merger with BioMarin Pharmaceutical Inc., becoming a wholly-owned subsidiary and terminating all public offerings of its securities.

check_boxKey Events

• Merger Completion

  Amicus Therapeutics, Inc. has completed its merger with Lynx Merger Sub 1, Inc., a wholly-owned subsidiary of BioMarin Pharmaceutical Inc., making Amicus a private entity.

• Deregistration of Securities

  As a direct result of the merger, Amicus has filed to deregister all previously registered but unsold securities, terminating all public offerings and sales.

auto_awesomeAnalysis

This POSASR filing confirms the completion of the merger between Amicus Therapeutics, Inc. and Lynx Merger Sub 1, Inc., a wholly-owned subsidiary of BioMarin Pharmaceutical Inc. As a result, Amicus Therapeutics is now a private, wholly-owned subsidiary of BioMarin, and its public offerings of securities have been terminated. This marks the final step in the acquisition process, following recent regulatory clearances, and effectively ends Amicus's existence as an independent publicly traded company. The stock trading near its 52-week high prior to this completion suggests a favorable outcome for shareholders.